Analyst consensus rating
Upstream Bio Analyst Rating: Buy
UPB is rated Buy by 8 analysts with a $33.50 target. As of 2026-08-26.
Direct answer
Upstream Bio's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.50.
Forecast evidence checked August 26, 2026.
Get free Upstream Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.18
- Average price target
- $33.50
- High price target
- $75.00
- Low price target
- $9.00
- Low target gap
- +25.3%
- Target upside
- +366.6%
- High target gap
- +944.6%
- Target range width
- 919.2%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Upstream Bio?
Upstream Bio has a verified Buy consensus. The same dataset has an average price target of $33.50.
How far are Upstream Bio's low and high targets from the recorded price?
The low target implies +25.3%, while the high target implies +944.6%.
How many analysts are included in Upstream Bio's consensus?
The verified consensus includes 8 analysts.
How is Upstream Bio's target upside or downside calculated?
The average target of $33.50 is divided by the recorded price of $7.18, then one is subtracted to produce +366.6%. This does not guarantee a future return.
When was Upstream Bio's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.